Caxton Associates (New York)’s Sangamo Therapeutics SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-177,960
| Closed | -$231K | – | 577 |
|
|
2023
Q2 | $231K | Sell |
177,960
-110,258
| -38% | -$143K | 0.03% | 392 |
|
|
2023
Q1 | $507K | Buy |
288,218
+123,145
| +75% | +$217K | 0.08% | 259 |
|
|
2022
Q4 | $518K | Buy |
+165,073
| New | +$518K | 0.03% | 213 |
|
|
2022
Q3 | – | Sell |
-88,549
| Closed | -$367K | – | 631 |
|
|
2022
Q2 | $367K | Hold |
88,549
| – | – | 0.04% | 319 |
|
|
2022
Q1 | $514K | Buy |
+88,549
| New | +$514K | 0.04% | 222 |
|